We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Entasis Therapeutics Holdings Inc | NASDAQ:ETTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.19 | 2.21 | 2.19 | 0 | 01:00:00 |
“We continued to make steady progress across all our pipeline programs in the first half of 2019,” commented Manos Perros, President and Chief Executive Officer of Entasis Therapeutics. “Earlier in April, we initiated the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 pivotal trial evaluating a fixed-dose combination of sulbactam plus durlobactam, or SUL-DUR (ETX2514SUL), as a potential treatment for carbapenem-resistant Acinetobacter baumannii infections. We also reported encouraging topline data from the Phase 1 study of ETX0282 which is being developed as a therapy for gram-negative infections caused by multidrug-resistant (MDR) Enterobacteriaceae. We also announced the addition of David Meek, current CEO of Ipsen S.A. as Chairman of our board, who brings significant healthcare experience and insight to the Company as we execute on our strategic objectives.”
Second Quarter and Recent Business Highlights
Second Quarter Financial Results
The Company reported a net loss of $13.4 million for the quarter ended June 30, 2019, compared to a net loss of $5.7 million for the quarter ended June 30, 2018. The increase in net loss was primarily related to an increase in research and development expenses and decreases in other income.
Research and development expenses were $10.7 million for the quarter ended June 30, 2019, compared to $9.5 million for the quarter ended June 30, 2018. The increase in research and development expenses was primarily attributable to clinical development expenses, primarily related to the advancement of our SUL-DUR product candidate.
General and administrative expenses were $3.4 million for the quarter ended June 30, 2019 compared to $2.5 million for the quarter ended June 30, 2018, as increased costs associated with additional headcount were offset by lower legal costs.
As of June 30, 2019, cash, cash equivalents and short-term investments were $59.5 million, compared to $74.6 million as of March 31, 2019. The Company believes its current cash position provides a runway into the fourth quarter of 2020.
About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis’ control. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactsTram Bui / Janhavi MohiteThe Ruth Group(646) 536-7035 / 7026tbui@theruthgroup.comjmohite@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com
(Financial Tables Follow)
Entasis Therapeutics Holdings Inc. | |||||||||||||||||||||||
Condensed Consolidated Statements of Operations | |||||||||||||||||||||||
Unaudited | |||||||||||||||||||||||
(in thousands, except share and per share data) | |||||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||||||||||
Revenue | $ | - | $ | 5,000 | $ | - | $ | 5,000 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development | 10,677 | 9,479 | 21,679 | 18,029 | |||||||||||||||||||
General and administrative | 3,421 | 2,548 | 6,609 | 5,766 | |||||||||||||||||||
Total operating expenses | 14,098 | 12,027 | 28,288 | 23,795 | |||||||||||||||||||
Loss from operations | (14,098 | ) | (7,027 | ) | (28,288 | ) | (18,795 | ) | |||||||||||||||
Other income: | |||||||||||||||||||||||
Grant income | 372 | 1,750 | 1,201 | 2,839 | |||||||||||||||||||
Interest income | 417 | 16 | 908 | 28 | |||||||||||||||||||
Total other income | 789 | 1,766 | 2,109 | 2,867 | |||||||||||||||||||
Loss before income taxes | (13,309 | ) | (5,261 | ) | (26,179 | ) | (15,928 | ) | |||||||||||||||
Provision for income taxes | 73 | 472 | 144 | 472 | |||||||||||||||||||
Net loss | $ | (13,382 | ) | $ | (5,733 | ) | $ | (26,323 | ) | $ | (16,400 | ) | |||||||||||
Net loss per share—basic and diluted | $ | (1.02 | ) | $ | (453.60 | ) | $ | (2.00 | ) | $ | (1,297.57 | ) | |||||||||||
Weighted average common stock outstanding—basic and diluted | 13,131,291 | 12,639 | 13,128,956 | 12,639 | |||||||||||||||||||
Entasis Therapeutics Holdings Inc. | |||||||||||||||
Condensed Consolidated Balance Sheets | |||||||||||||||
Unaudited | |||||||||||||||
(in thousands) | |||||||||||||||
June 30, | December 31, | ||||||||||||||
2019 | 2018 | ||||||||||||||
Cash, cash equivalents and investments | $ | 59,473 | $ | 85,092 | |||||||||||
Other assets | 7,016 | 4,182 | |||||||||||||
Total assets | $ | 66,489 | $ | 89,274 | |||||||||||
Total liabilities | $ | 8,649 | $ | 6,391 | |||||||||||
Total stockholders' equity | 57,840 | 82,883 | |||||||||||||
Total liabilities and stockholders’ equity | $ | 66,489 | $ | 89,274 | |||||||||||
1 Year Entasis Therapeutics Chart |
1 Month Entasis Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions